Literature DB >> 8896195

Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure.

M A Poli1, V R Rivera, M L Pitt, P Vogel.   

Abstract

Parenteral vaccination with ricin toxoid, although protective against death after a lethal aerosol ricin challenge, only partially protects against lung lesions. Therefore, we tested whether passive protection with aerosolized specific anti-ricin IgG (goat polyclonal, affinity-purified) could protect against both lethality and lung lesions in unvaccinated mice. Healthy CD-l mice were administered antibody (Ab) by small particle aerosol. Group 1 received non-specific control Ab (2160 mg/min/m3), and groups 2 and 3 received anti-ricin IgG (960 and 3280 mg/min/m3, respectively). Each group was challenged with a lethal dose of aerosolized ricin 1 hr after Ab exposure. All group 1 (control Ab) mice developed diffuse airway epithelial necrosis, with severe interstitial edema and inflammation involving all lung lobes, and died 48-96 hr post-challenge (PC). In contrast, in groups 2 and 3 at 24 hr PC, lung lesions were absent to very mild although there was rare epithelial necrosis in the upper airways in both groups. By 48 hr PC, necrosis of the tracheal epithelium and peritracheal inflammation were noted in some group 3 mice only. By 4 days PC, lungs and airways did not differ from cage controls in most group 2 and 3 mice. Weight gain in group 2 and 3 mice paralleled that of control mice. At 14 days PC, lungs were no different in controls than in group 3 mice. However, two non-survivors in group 3 had obstructions due to proximal airway epithelial damage. All group 2 mice survived, although a mild lymphoplasmacytic perivasculitis was present at 14 days PC which was not noted in the group 3 mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8896195     DOI: 10.1016/0041-0101(96)00047-5

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  20 in total

1.  Modeling of toxin-antibody interaction and toxin transport toward the endoplasmic reticulum.

Authors:  Vladas Skakauskas; Pranas Katauskis
Journal:  J Biol Phys       Date:  2015-08-26       Impact factor: 1.365

2.  RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol.

Authors:  Joan E Smallshaw; James A Richardson; Ellen S Vitetta
Journal:  Vaccine       Date:  2007-08-30       Impact factor: 3.641

3.  Protective effects of anti-ricin A-chain antibodies delivered intracellularly against ricin-induced cytotoxicity.

Authors:  Feng Wu; Shaoan Fan; Frank Martiniuk; Seth Pincus; Sybille Müller; Heinz Kohler; Kam-Meng Tchou-Wong
Journal:  World J Biol Chem       Date:  2010-05-26

Review 4.  Immunity to ricin: fundamental insights into toxin-antibody interactions.

Authors:  Joanne M O'Hara; Anastasiya Yermakova; Nicholas J Mantis
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 5.  Antibodies for biodefense.

Authors:  Jeffrey W Froude; Bradley Stiles; Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

6.  Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity.

Authors:  Thibaut Pelat; Michael Hust; Martha Hale; Marie-Paule Lefranc; Stefan Dübel; Philippe Thullier
Journal:  BMC Biotechnol       Date:  2009-06-30       Impact factor: 2.563

7.  Evidence for widespread epithelial damage and coincident production of monocyte chemotactic protein 1 in a murine model of intestinal ricin intoxication.

Authors:  J Marina Yoder; Rabia U Aslam; Nicholas J Mantis
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

8.  Intrapulmonary delivery of ricin at high dosage triggers a systemic inflammatory response and glomerular damage.

Authors:  John Wong; Veselina Korcheva; David B Jacoby; Bruce Magun
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

9.  Pathology of lethal and sublethal doses of aerosolized ricin in rhesus macaques.

Authors:  Manoj Bhaskaran; Peter J Didier; Satheesh K Sivasubramani; Lara A Doyle; Jane Holley; Chad J Roy
Journal:  Toxicol Pathol       Date:  2013-06-11       Impact factor: 1.902

10.  A pilot clinical trial of a recombinant ricin vaccine in normal humans.

Authors:  Ellen S Vitetta; Joan E Smallshaw; Elaine Coleman; Hasan Jafri; Callie Foster; Robert Munford; John Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.